A multicenter, open-label, randomized, phase III study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab versus treatment of physician's choice in patients with advanced endometrial cancer Meeting Abstract
| Authors: | Makker, V.; Colombo, N.; Herráez, A. C.; Santin, A.; Colomba, E.; Miller, D.; Fujiwara, K.; Pignata, S.; Baron-Hay, S.; Ray-Coquard, I.; Shapira-Frommer, R.; Ushijima, K.; Sakata, J.; Yonemori, K.; Kim, Y. M.; Guerra, E.; Sanli, U.; McCormack, M.; Huang, J.; Smith, A.; Keefe, S.; Dutta, L.; Orlowski, R.; Lorusso, D. |
| Abstract Title: | A multicenter, open-label, randomized, phase III study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab versus treatment of physician's choice in patients with advanced endometrial cancer |
| Meeting Title: | 2021 Society of Gynecologic Oncology - 52nd Annual Meeting on Women's Cancer |
| Journal Title: | Gynecologic Oncology |
| Volume: | 162 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2021 Mar 19-25 |
| Meeting Location: | Virtual |
| ISSN: | 0090-8258 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2021-08-01 |
| Start Page: | S4 |
| Language: | English |
| ACCESSION: | WOS:000687070800003 |
| PROVIDER: | wos |
| DOI: | 10.1016/S0090-8258(21)00657-0 |
| Notes: | Meeting Abstract: 2 -- Source: Wos |
